Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The study proceeds with prospective, randomized, open and controlled clinical trials. The
subject of the investigator's study was the first patient diagnosed with dilated
cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet
the selection / exclusion criteria were randomly assigned to each group, and the experimental
group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the
control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.